Popular terms

Leukemia topics
Myelogenous
Myelogenous Leukemia
Proliferative
Autoimmune
Stem Cells
Breast Cancer
Rheumatoid Arthritis
Myeloid Leukemia
Acute Myelogenous Leukemia
Lymphocytic
Chronic Lymphocytic Leukemia
Lymphocytic Leukemia
Epigenetic
Multiple Myeloma
Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Leukemia patents



      

This page is updated frequently with new Leukemia-related patent applications.




Date/App# patent app List of recent Leukemia-related patents
04/07/16
20160097770 
 Methods for diagnosis, prognosis and methods of treatment patent thumbnailMethods for diagnosis, prognosis and methods of treatment
This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of cells present in a sample (e.g.
Nodality, Inc.


04/07/16
20160096825 
 Furanone compounds as kinase inhibitors patent thumbnailFuranone compounds as kinase inhibitors
The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as raf kinase, especially braf kinase, inhibitors, which are useful therapeutic agents for treatment of raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds..
Eternity Bioscience Inc.


04/07/16
20160096820 
 Inhibitors of inv(16) leukemia patent thumbnailInhibitors of inv(16) leukemia
This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (aml). The inv(16) fusion results in expression of the cbfβ-smmhc fusion protein in the blood cells of afflicted patients.
University Of Virginia Patent Foundation


04/07/16
20160095870 
 Methods of forming cyclopirox or derivatives thereof in a subject by administration of prodrug patent thumbnailMethods of forming cyclopirox or derivatives thereof in a subject by administration of prodrug
A method of forming a compound in a subject can include: providing a composition having a prodrug compound represented by a structure of formula 1 or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the composition to a subject such that the prodrug compound has a phosphoryloxyalkyl prodrug moiety removed therefrom to form the compound in the subject and to form the separate phosphoryloxyalkyl compound. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, various cancers (e.g., bladder, breast, etc.), dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum, and microsporum canis, candidiasis (moniliasis), candida albicans, tinea (pityriasis) vesicolor, malassezia furfur, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma..
The University Of Kansas


04/07/16
20160095863 
 Combination treatment of acute myeloid leukemia and myelodysplastic syndrome patent thumbnailCombination treatment of acute myeloid leukemia and myelodysplastic syndrome
The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof in combination with quizartinib or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).. .
Boehringer Ingelheim International Gmbh


03/31/16
20160090637 
 Pharmacogenomic biomarkers for b cell malignancies and methods of use thereof patent thumbnailPharmacogenomic biomarkers for b cell malignancies and methods of use thereof
The present invention relates to diagnosing drug-resistant chronic lymphocytic leukemia (cll) in a mammal.. .

03/24/16
20160083361 
 Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof patent thumbnailInhibitors of the ire-1/xbp-1 pathway and methods of using thereof
Disclosed are xbp-1/ire-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular b cell cancers, are also disclosed.
H. Lee Moffitt Cancer Center And Research Institute, Inc.


03/24/16
20160082071 
 Methods of treating myeloid leukemia patent thumbnailMethods of treating myeloid leukemia
There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a cxcr4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent..
Biokine Therapeutics Ltd.


03/24/16
20160081979 
 Method for separating therapeutic agent for chronic myelogenous leukemia from bark of liriodendron tulipifera l. patent thumbnailMethod for separating therapeutic agent for chronic myelogenous leukemia from bark of liriodendron tulipifera l.
The present invention provides a method for separating and preparing a therapeutic agent for chronic myelogenous leukimeia capable of effectively inhibiting growth of t315i, which is known as a mutation of a bcr-abl fusion gene that causes chronic myelogenous leukemia, comprising the steps of: 1) preliminary extracting by adding ethyl acetate to finely chopped bark of liriodendron tulipifera l., adding butanol to an extracted fluid for layer-separating an ethyl acetate layer and a butanol layer, removing the butanol layer, and decompression-condensing the remainder to obtain a crude extract; and 2) adding a c1-c3 lower alcohol aqueous solution and n-hexane to the obtained crude extract, removing lipids and water insoluble material dissolved in the n-hexane layer, and obtaining and separating a lower alcohol aqueous solution layer to separate and refine highly pure epi-tulipinolide and costunolide.. .
Cho Dang Pharm. Co., Ltd.


03/24/16
20160081978 
 Pharmaceutical composition containing liriodendron tulipifera l. extract for treating chronic myelogenous leukemia patent thumbnailPharmaceutical composition containing liriodendron tulipifera l. extract for treating chronic myelogenous leukemia
The present invention relates to a pharmaceutical composition containing, as an active ingredient, a liriodendron tulipifera l. Bark extract for treating chronic myelogneous leukemia.
Cho Dang Pharm. Co., Ltd.


03/24/16
20160081973 

Activator of mitochondria


In order to allow differentiation induction of cancer cells into normal cells, the present invention provides an activator of mitochondria containing a component expected to have an epigenetic action, or provides a cell differentiation inducer having a novel composition that has an action to activate mitochondria. The activator of mitochondria contains, as an effective component, 0.03 to 300 μg/ml of a single component of kaempferol, or a mixture component of kaempferol and glycerol.
Flora Co., Ltd.


03/10/16
20160070852 

Prognosis prediction for acute myeloid leukemia by a 3-microrna scoring method


The present invention relates to a scoring method for predicting the survival of a de novo aml patient based on the expression level of micrornas mir-9, mir-155 and mir-203 in the patient. Patients with higher scores are associated with shorter overall survival.
National Taiwan University


03/10/16
20160068610 

Glutamate dehydrogenase in idh1- and idh2-mutated cancers


Expression of glud1, glud2, or both is tested in gliomas, leukemias, or suspected gliomas and leukemias. Up-regulation of expression is found in idh1/idh2 mutant cancers.
Duke University


03/10/16
20160067336 

Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody


The present disclosure provides methods of treating diseases or disorders with oral cytidine analogs (e.g., 5-azacytidine) in combination with anti-pd1/anti-pdl1 antibodies (e.g., pembrolizumab or durvalumab). The diseases or disorders include, but are not limited to, relapsed or refractory myelodysplastic syndromes, acute myeloid leukemia, ovarian cancer, or non-small cell lung cancer..
Celgene Corporation


03/10/16
20160067240 

Novel allosteric inhibitors of thymidylate synthase


The current invention is directed to a class of compounds that inhibit the function of thymidylate synthase. Thymidylate synthase inhibition was noted to result in inhibition of tumor cell grow and killing of tumor cells.
University Of Florida Research Foundation, Inc.


03/03/16
20160060709 

Novel biomarkers for acute myeloid leukemia


Methods for the diagnosis of leukemias, and more specifically aml, such as mll-af9 aml, in a subject, based on the assessment of the expression or activity of one or more of the genes listed in tables 1 and 2 are disclosed. The use of antibodies or antigen-binding fragments thereof that bind to one or more of proteins showing preferential expression at the cell surface of aml leukemic cells for treating aml is also disclosed..
UniversitÉ Laval


03/03/16
20160060613 

Pegylated l-asparaginase


Disclosed is a conjugate of a protein having substantial l-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 da and the protein is an l-asparaginase from erwinia.
Alize Pharma Ii Sas


03/03/16
20160060342 

Markers of acute myeloid leukemia stem cells


Markers of acute myeloid leukemia stem cells (amlsc) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets..
The Board Of Trustees Of The Leland Stanford Junior University


03/03/16
20160058741 

Thiadiazolidinone derivatives


The present invention relates to compounds of the formulae herein, their acceptable salts, solvates, hydrates and polymorphs thereof. The compounds of this invention are useful in treatment of disease, particularly leukemia.
University Of Rochester


03/03/16
20160058719 

Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis


The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent.
Amderma Pharmaceuticals, Llc


02/25/16
20160053333 

Novel haplotype tagging single nucleotide polymorphisms and use of same to predict childhood lymphoblastic leukemia


The present invention is directed to novel haplotype tagging single nucleotide polymorphisms (snps) in specific regions outside the hfe gene that serve as a reliable biomarker for a decreased risk for childhood lymphoblastic leukemia (all) in a child. There is provided herein methods and reagents for assessing the haplotype tagging snps selected from the group consisting of rs807212, rs198853, rs9467664, rs2213284, rs2230655 and rs12346.
Medical Diagnostic Laboratories, Llc


02/25/16
20160052915 

Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof


The present invention relates to the rohitukine (5,7-dihydroxy-8-(3-hydroxy-1-methyl-piperidin-4-yl)-4h-chromen-4-ones) analogs of formula a and pharmaceutically acceptable salts thereof. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various proliferative disorders such as melanoma, leukemia, breast cancer and prostate cancer etc.
Council Of Scientific And Industrial Research


02/25/16
20160051553 

Molecular and herbal combinations with methotrexate for treating diseases and inflammatory ailments


A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a methotrexate regimen along with periodic doses of an herbal combination including sheng di huang, da huang or jin yin hua or combinations thereof.. .
Sirbal, Ltd.


02/18/16
20160046647 

Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof


The present invention relates generally to thienopyrimidine and thienopyridine class compounds and methods of use thereof. In particular embodiments, the present invention provides compositions comprising thienopyrimidine and thienopyridine class compounds and methods of use to inhibit the interaction of menin with mll1, mll2 and mll-fusion oncoproteins (e.g., for the treatment of leukemia, solid cancers and other diseases dependent on activity of mll1, mll2, mll fusion proteins, and/or menin)..
The Regents Of The University Of Michigan


02/18/16
20160046602 

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..

02/18/16
20160045593 

Vaccine against bovine leukemia virus


The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors.
Instituto Nacional De TecnologÍa Agropecuaria


02/18/16
20160045504 

Compositions and methods for treatment of leukemia


The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with mll and mll-fusion oncoproteins, and well as systems and methods to screen for such compositions..
University Of Virginia Patent Foundation


02/11/16
20160040129 

Conditionally immortalized long-term stem cells and methods of making and using such cells


Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (aml) and cells and methods related to such mouse model are also described..
The Regents Of The University Of Colorado


02/11/16
20160038529 

Combination therapy for mds


Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (mds) and acute myeloid leukemia (aml). The disclosed methods include administering to an individual in need of such treatment a composition that may include an irak1/4 inhibitor.
Children's Hospital Medical Center


02/04/16
20160031929 

Inhibitors of cyp17a1


Compounds according to formula i or ii are provided. Such compounds are useful in treating cancers, such as leukemia, colon cancer, breast cancer, or prostate cancer by beneficially inhibiting cyp17a1.
University Of Kansas


02/04/16
20160031883 

2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer


The present invention provides 2-substituted imidazo[4,5-d]phenanthroline compounds, which are capable of inhibiting proliferation of one or more renal cancer cells, pancreatic cancer cells, prostate cancer cells, colon cancer cells, leukemia cells, brain cancer/tumour cells or non-small cell lung cancer cells.. .
Aptose Biosciences Inc.


02/04/16
20160030458 

Treatment of leukemia with histone deacetylase inhibitors


Provided herein are combinations comprising an hdac inhibitor and azacitidine for the treatment of leukemia in a subject in need thereof. Provided herein are combinations comprising an hdac inhibitor and azacitidine for the treatment of acute myelogenous leukemia in a subject in need thereof.
Acetylon Pharmaceuticals Inc.


01/28/16
20160024212 

Humanized anti-hla-dr antibodies


The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
Immunomedics, Inc.


01/28/16
20160024167 

Methods and compositions based on diphtheria toxin-interleukin-3 conjugates


The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (dt-il3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the dt-il3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3.
Scott & White Memorial Hospital


01/21/16
20160017429 

Method for prognosing the survival of patients suffering from chronic myelomonocytic leukaemia


The present invention relates to a method of prognostic of the survival of human subject suffering from chronic myelomonocytic leukemia (cmml) based on the differential expression of six genes in a test sample of pbmc cells obtained from said human subject and in a control sample of normal cells, wherein said expression level indicates if the human subject from which the test sample has been obtained will have long-term or short-term survival.. .
Acobiom


01/14/16
20160009815 

Methods for manipulating phagocytosis mediated by cd47


Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..
The Board Of Trustees Of The Leland Stanford Junior University


01/14/16
20160009814 

Methods for manipulating phagocytosis mediated by cd47


Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..
The Board Of Trustees Of The Leland Stanford Junior University


01/14/16
20160009683 

Antiproliferative compounds and methods of use thereof


Compounds of formula i for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds.
Celgene Corporation


01/07/16
20160002629 

Diagnostic and treatment for chronic and acute phase myeloid leukemia


Disclosed are methods of predicting responsiveness of a cancer cell to a tyrosine kinase inhibitor, and methods of predicting the risk of progression of a cancer cell to a more aggressive form. Also provided are methods of reducing proliferation or promoting differentiation of a cancer cell having reduced level of numb or increased level of msi.
Duke University


01/07/16
20160002354 

Antibodies to bone marrow stromal antigen 1


The invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.
Oxford Biotherapeutics Ltd


01/07/16
20160002333 

Bispecific cd33 and cd3 binding proteins


Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


01/07/16
20160000877 

Compositions and methods for modulating gamma-c-cytokine activity


The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc


01/07/16
20160000864 

Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment


The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer.

01/07/16
20160000829 

Methods for treating chronic lymphocytic leukemia (cll)


The present invention relates generally to the treatment of pml by infusion of activated and expanded autologous lymphocytes.. .
The Trustees Of The University Of Pennsylvania


01/07/16
20160000796 

Pharmaceutical composition for use in prevention or treatment of cancer


Abacavir, a nucleoside analogue reverse transcriptase inhibitor, has been found to exhibit an anti-cancer activity on atl cells in vitro without inhibiting dna replication of normal cells. Abacavir or a pharmaceutically acceptable derivative thereof is useful as an active ingredient of a pharmaceutical composition for use in the prevention or the treatment of cancer, in particular a cancer whose dna repair system is impaired such as breast cancer or adult t-cell leukemia..
Kyoto University




Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.661

5255

0 - 1 - 102